StemCell Therapy

TORONTO and HOUSTON, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced new clinical data on anti-tumor activity from the Phase 1/2 ABILITY study of MDNA11, the Company’s “beta-only” long-acting IL-2 super-agonist. These data include a confirmed partial response (PR) in a fourth-line metastatic pancreatic ductal adenocarcinoma (PDAC) patient that had previously failed chemo and checkpoint inhibitor therapies. The confirmatory scan for this patient continues to show further tumor reduction compared to prior scans, suggesting durable anti-cancer activity following MDNA11 monotherapy. Overall, five of fourteen evaluable patients in the ABILITY study’s low and mid-stage dose escalation cohorts have achieved tumor control (PR or stable disease (SD)) with MDNA11 monotherapy.

Go here to see the original:
Medicenna Reports Confirmed Partial Response in Pancreatic Cancer and Clinical Update on MDNA11’s Monotherapy Dose Escalation Portion of the Ongoing...

Appointment of Stuart Loesch as President Leverages His Strong Leadership Abilities and Extensive Expertise in Allergy and Pharmaceutical Development

Excerpt from:
Intrommune Expands and Strengthens Senior Leadership Team

NEW YORK, Sept. 28, 2022 (GLOBE NEWSWIRE) --  Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company committed to enabling normal lives for people with autoimmune diseases, today announced a new anti-FcRn, IMVT-1402, at Roivant’s Investor Day at 11:00am on September 28, 2022. The presentation can be accessed at the Investor Relations section of the Company’s website, located at www.immunovant.com.

Follow this link:
Immunovant Announces IMVT-1402, a Next Generation Anti-FcRn  

Recognized for pioneering work in field of integrin receptor biology, leading to new treatments for multiple autoimmune disorders

Read more:
Morphic Congratulates Timothy A. Springer, PhD as 2022 Albert Lasker Basic Medical Research Award Honoree

PHILOGEN S.p.A.

Link:
Board of Directors Approves Half-Year Financial Report as of June 30, 2022

WVE-006 is the most advanced candidate for AATD designed to restore functional wild-type AAT protein and reduce Z-AAT protein aggregation with potential for disease modification in both lung and liver phenotypes

Read the original here:
Wave Life Sciences Highlights Therapeutic Potential for WVE-006 for Alpha-1 Antitrypsin Deficiency and Progress Bringing RNA Editing to the Clinic...

WARRINGTON, Pa., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular disorders, today reported that the results of its positive Phase 2 istaroxime study in early cardiogenic shock were published in the European Journal of Heart Failure (https://doi.org/10.1002/ejhf.2629). Cardiogenic shock is caused by a failing heart resulting in diminished cardiac output to the body and is characterized by very low blood pressure and hypoperfusion to end-organs. It requires urgent treatment and has a high morbidity and mortality. Windtree conducted a study called SEISMiC of istaroxime in patients experiencing early cardiogenic shock due to heart failure.

See the original post:
Windtree Therapeutics Announces Positive Istaroxime Phase 2 Study in Early Cardiogenic Shock (SEISMiC) Published in the European Journal of Heart...

SOUTH SAN FRANCISCO, Calif., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical?stage T-cell reprogramming company dedicated to developing curative cell therapies for patients with solid tumors, announced that Rahsaan W. Thompson has joined the executive management team as chief legal officer. A biopharmaceutical industry veteran, Mr. Thompson has more than 20 years of experience with development stage and commercial companies.

Continue reading here:
Lyell Immunopharma Announces the Appointment of Rahsaan Thompson as Chief Legal Officer

Acquisition includes late-stage rare disease portfolio with anticipated 2023 clinical milestones and first potential product approval as early as late 2024

Read the rest here:
Idera Pharmaceuticals Acquires Aceragen

Lille (France), Cambridge, MA; September 28, 2022 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe and chronic liver diseases, today announced its first half-year 2022 financial results and provided a corporate update.

View original post here:
GENFIT Reports First Half-Year 2022 Financial Results and Provides Corporate Update

NEW YORK, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the appointment of Mark Frattini, M.D., Ph.D., as Chief Medical Officer, effective immediately.

Original post:
Cellectis Appoints Mark Frattini, M.D., Ph.D. as Chief Medical Officer

SOUTH SAN FRANCISCO, Calif., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, has filed a response to the complaint of, and counterclaims against, Janssen Biopharma in California State Superior Court for the County of San Mateo.

Read the original:
Aligos Therapeutics Files Response to Janssen Biopharma Lawsuit and Lodges Counterclaims Alleging Unfair Competition and Promissory Fraud

Saint Herblain (France), September 28, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) (the “Company”), a specialty vaccine company, today announced its intention to issue and sell, subject to market conditions, approximately $40 million of its ordinary shares in a global offering to specified categories of investors comprised of (i) a public offering of its American Depositary Shares (“ADSs”), each representing two ordinary shares, in the United States (the “U.S. Offering”) and (ii) a concurrent private placement of its ordinary shares in certain jurisdictions outside of the United States (the “European Private Placement” and together with the U.S. Offering, the “Global Offering”).

Go here to read the rest:
Valneva Announces Launch of Approximately $40 Million in a Proposed Global Offering of American Depositary Shares and Ordinary Shares

VANCOUVER, British Columbia, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (US-OTC: SRBCF) (“Sirona”) announces the release of a corporate update which highlights the company’s recent team meeting in France, the current pipeline, and the latest deal structure.

Read the original post:
Sirona Biochem Issues Corporate Update

Dupixent® (dupilumab) approved by FDA as the first and only treatment indicated for prurigo nodularis

Read the original here:
Press Release: Dupixent® (dupilumab) approved by FDA as the first and only treatment indicated for prurigo nodularis

Through its wholly owned subsidiary BSPG Laboratories, Brains Bio’s new facility is set to become a global research center for cannabinoid research, testing, and commercialization of natural EU GMP API’s Through its wholly owned subsidiary BSPG Laboratories, Brains Bio’s new facility is set to become a global research center for cannabinoid research, testing, and commercialization of natural EU GMP API’s

Follow this link:
Brains Bioceutical Opens UK’s Largest EU GMP-Grade Licensed Cannabinoid Research and Commercial Production Facility

Ad hoc announcement pursuant to Art. 53 LR

Read more:
Santhera Announces Preliminary 2022 Half-year Financial Results Ahead of Full Report Publication by End of October

OSLO, Norway, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced that its Chief Executive Officer, Michael Engsig, and Chief Business Officer & Co-founder, Agnete Fredriksen, will present at the H.C. Wainwright 24th Annual Global Investment Conference on Tuesday, September 13, 2022 at 11:00 a.m. ET / 5:00 p.m. CET and are available for 1:1 investor meetings.

Link:
Nykode Therapeutics to present at H.C. Wainwright 24th Annual Global Investment Conference

New York, NY, and Tel Aviv, ISRAEL, Sept. 09, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today released the Nasdaq MarketSite interview between Moneta Advisory Group’s Managing Partner Marc LoPresti and CEO Gerald Commissiong, discussing the impact of Long COVID on the economy and how SARS-CoV-2 viral persistence is damaging population-level immunity leading to the rise of viral outbreaks such as MonkeyPox. A link to the interview can be found at: https://youtu.be/55pv1zKCDgI.

Read the rest here:
Todos Medical CEO Discusses Long COVID Economic Impact with Moneta Advisory Managing Partner Marc LoPresti

Go here to see the original:
Orion Corporation: Acquisition of Own Shares 09.09.2022